Drug Trial Radar · NCT06059846
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Last checked: Nov 19, 2026Latest source record: Mar 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,690
Actual
Start
Dec 21, 2023
Primary completion
Jan 27, 2025
Study completion Feb 6, 2025
Sponsor
- Lead sponsor
- Spero TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Sep 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (greater than or equal to (≥)18 years of age) with cUTI or AP.
Conditions
- Urinary Tract Infection
- Acute Pyelonephritis
Interventions
TBP-PI-HBrDrug
TBP-PI-HBr film-coated immediate-release tablets.
Imipenem-cilastatinDrug
Sterile powder for reconstitution administered as IV.
Dummy InfusionDrug
0.9% sodium chloride administered as IV infusion.
Dummy TabletsDrug
TBP-PI-HBr matching dummy tablets.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Overall Response at the Test-of-Cure (TOC) Visit in the Microbiological Intent-to-Treat (Micro-ITT) PopulationTime frame: At Day 17 (TOC)
Locations
85 sites in 19 countries. Site status is shown where the registry gives one.
Medical facility
Miami, Florida
Medical Facility
Miami, Florida
Medical Facility
Buenos Aires, Argentina
Medical Facility
Córdoba, Argentina
Medical Facility
La Plata, Argentina
Medical Facility
Mendoza, Argentina
Medical Facility
San Miguel de Tucumán, Argentina
Medical Facility
Villa Regina, Argentina
Medical Facility
Banja Luka, Bosnia and Herzegovina
Medical Facility
Sarajevo, Bosnia and Herzegovina
Medical Facility
Tuzla, Bosnia and Herzegovina
Medical Facility
Barueri, Brazil
Medical Facility
Campinas, Brazil
Medical Facility
Curitiba, Brazil
Medical Facility
Porto Alegre, Brazil
Medical Facility
São José do Rio Preto, Brazil
Medical Facility
Blagoevgrad, Bulgaria
Medical Facility
Dobrich, Bulgaria
Medical Facility
Gabrovo, Bulgaria
Medical facility
Lom, Bulgaria
Medical Facility
Pleven, Bulgaria
Medical Facility
Plovdiv, Bulgaria
Medical facility
Rousse, Bulgaria
Medical facility
Shumen, Bulgaria
Medical Facility
Sliven, Bulgaria
Medical facility
Sofia, Bulgaria
Medical Facility
Varna, Bulgaria
Medical Facility
Čakovec, Croatia
Medical Facility
Slavonski Brod, Croatia
Medical Facility
Split, Croatia
Medical Facility
Zagreb, Croatia
Medical Facility
Kohtla-Järve, Estonia
Medical Facility
Pärnu, Estonia
Medical Facility
Tallinn, Estonia
Medical Facility
Tartu, Estonia
Medical Facility
Võru, Estonia
Medical facility
Tbilisi, Georgia
Medical Facility
Alexandroupoli, Greece
Medical Facility
Athens, Greece
Medical Facility
Ioannina, Greece
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.